جلد 6، شماره 4 - ( 8-1401 )                   جلد 6 شماره 4 صفحات 16-6 | برگشت به فهرست نسخه ها

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mansouri S, Samadi T, Teimurzadeh A, Majidzadeh-A K, Farahmand L. A Review of the Molecular Mechanisms of EGFR and IGFR Receptors in Tamoxifen Resistance in Breast Cancer. Multidiscip Cancer Investig 2022; 6 (4) :6-16
URL: http://mcijournal.com/article-1-360-fa.html
A Review of the Molecular Mechanisms of EGFR and IGFR Receptors in Tamoxifen Resistance in Breast Cancer. نشریه بین المللی چند تخصصی سرطان 1401; 6 (4) :16-6

URL: http://mcijournal.com/article-1-360-fa.html


چکیده:   (211 مشاهده)
In 1980, tamoxifen was introduced as an effective adjuvant endocrine therapy for breast cancer, resulting in a significant increase in overall survival. Nevertheless, the development of acquired resistance limited the efficacy of tamoxifen therapy. Several molecular mechanisms have been proposed to explain the probable process of tamoxifen resistance. In vitro studies have suggested that alterations in the expression of cytoplasmic growth cascades such as insulin-like growth factor receptor (IGFR) and epidermal growth factor receptor (EGFR) along with associated downstream signaling pathways such as ERK1, ERK2, and ERK6 are the main cause of resistance to tamoxifen. In this review, we investigated the role of estrogen receptor-α (ER-α), EGFR, IGFR, and their downstream signaling pathways in tamoxifen resistance. The present study attempted to find out possible culprits of tamoxifen resistance to improve treatment efficacy in breast cancer patients.
متن کامل [PDF 1000 kb]   (47 دریافت)    

دریافت: 1401/5/10 | پذیرش: 1401/7/27 | انتشار الکترونیک: 1401/8/14

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به نشریه بین المللی چند تخصصی سرطان می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2023 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb